All Articles

As Riot Platforms preps its Q2 earnings call, the real story isn't just Bitcoin. It's a strategic pivot to building the massive infrastructure for our digital future.

A landmark FDA approval allows Walter Reed to 3D-print cranial implants on-site, a strategic shift in military medicine powered by 3D Systems' expertise.

As NAVs fall, Cox Capital expands its discounted tender offers for non-traded BDCs, creating a crucial exit for investors and reshaping the private credit landscape.

A new biotech, CORE Biomedicine, armed with Eisai's preclinical assets and a $21M Series A, aims to upend oncology by targeting cancer's 'lineage' identity.

Dasher Neuroscience completes Phase 2 enrollment for its AI-designed drug for MSA, a fatal disease with no cure, signaling a major step toward a first-in-class therapy.

Futuri's Content Automation boasts an 80% cut in production time. As AI enters the newsroom, it forces a critical look at the future of journalism itself.

With $21M in funding and a novel 'lineage-based' approach, CORE Biomedicine is moving beyond genomics to target the root cause of cancer's identity.

A new partnership between FordDirect and Dealer Pay is more than a vendor deal. It’s a blueprint for modernizing the car-buying journey for millions.

The shift to usage-based pricing is seductive, but scaling it is treacherous. A new guide reveals why back-office operations are the real key to growth.

A new report reveals a hidden crisis: millions of working Americans are food insecure but earn too much for aid. This isn't a charity case; it's a systemic flaw.

NextPlat declares a strategic turnaround, but the real story is its complex model: blending high-margin healthcare with niche satellite tech. Can it deliver?

Nauticus Robotics' new AI-driven electric manipulator promises to slash costs and boost efficiency, signaling a major shift for the subsea industry.

The addition of a top international tax expert is more than a personnel move; it's the first major signal of how TPG's capital is arming Smith + Howard for a national expansion.

While giants chase scale, one firm's deep specialization in P&C insurance is earning top marks for both innovation and client experience. Here's why.

Parlance is upgrading healthcare IVR with advanced AI, enhancing patient calls without forcing costly system replacements. Here's why this strategy matters.

Guardian Capital's new fund deploys AI to analyze the AI sector, offering a dynamic alternative to static ETFs for investors chasing the tech megatrend.

New drilling at the Shovelnose project confirms thick, high-grade gold, including a record 200 g/t hit, as a major funding deal accelerates its path to production.

Interbrand and Clootrack's new AI platform transforms brand management from a periodic report into a live operating system, connecting every customer whisper to C-suite strategy.

Two small firms just secured a patent until 2045 on a decades-old drug. It's a masterclass in strategy, revealing the future of pharmaceutical value.